Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-31
2010-02-09
Landau, Sharmila Gollamudi (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S224000
Reexamination Certificate
active
07659287
ABSTRACT:
Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
REFERENCES:
patent: 3536809 (1970-10-01), Allplezwqeig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5059595 (1991-10-01), Le Grazie et al.
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5112598 (1992-05-01), Biesalski
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5556611 (1996-09-01), Biesalski
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van der Linden et al.
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 97/39745 (1997-10-01), None
patent: WO 99/47196 (1999-09-01), None
patent: WO 02/058690 (2002-08-01), None
patent: WO 2004/011410 (2004-02-01), None
patent: WO 2004/033427 (2004-04-01), None
patent: WO 2004/065351 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO 2004/089896 (2004-10-01), None
patent: WO 2004/111003 (2004-12-01), None
patent: WO 2006/138508 (2006-12-01), None
Draper et al. “11b-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action” J. Endocrinology, 2005, 186, 251-271.
Rew et al. “Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11B-HSD1 inhibitors” Bioorg. Med. Chem. Lett. 2009, 19, 1797-1801.
Barf et al.,J. Med. Chem., 2002, 45: pp. 3813-3815.
Bellows, C.G., et al.,Bone23. 1998, : pp. 119-125.
Billaudel, B. and B.C.J. Sutter (1979)Horm. Metab. Res.11: pp. 555-560.
Buchwald et al.,Surgery, 1980, 88, p. 507.
Bujalska, I.J., S. Kumar, and P.M. Stewart (1997)Lancet349: pp. 1210-1213.
Burger's Medicinal Chemistry and Drug Discovery6thed. (Donald J. Abraham ed., 2001, Wiley).
Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, pp. 3099-3108.
Cooper, M.S. et al.,Bone27, 2000, pp. 375-381.
Dahl et al., Poster 524 atAmerican Association of Cancer Research, San Francisco, Calif., Apr. 1-5, 2000.
Davani, B. et al. (2000) J. Biol. Chem. Nov. 10, 2000; 275(45): pp. 34841-34844.
de Quervain, D.J. et al.,Nature, 1998, 394: pp. 787-790.
Design and Application of Prodrugs(H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).
During et al.,Ann. Neurol., 1989,25, p. 351.
Engelke et al., Poster 342 atAmerican Association of Cancer Research, San Francisco, Calif., Apr. 1-5, 2000.
English et al., J. Clin.Endocrinol.Metab. 1999, 84: pp. 2080-2085.
Fraser et al.,Hypertension1999, 33: pp. 1364-1368.
Ge et al.,Biology of Reproduction1999, 60: pp. 855-860.
Geissler et al.,Nat. Genet.1994, 7: pp. 34-39.
Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115 (1984).
Halleux, C.M. et al. (1999)J. Clin. Endocrinol. Metab.84: pp. 4097-4105.
Houssay,Endocrinology1942, 30: pp. 884-892.
Howard et al., 1989,J. Neurosurg.71, p. 105.
Ishii et al,J. Org. Chem, 2000, 65, pp. 1597-1599.
J. Zhang, et al.Biochemistry, 44, 2005, pp. 6948-6957.
Jamieson et al. (2000) J. Endocrinol. 165: pp. 685-692.
Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-380.
Kim et al.,J. Endocrinol.1999, 162: pp. 371-379.
Kitawaki et al.,J. Clin. Endocrin. Metab., 2000, 85: pp. 1371-3292-3296.
Kotelevtsev, Y. et al., (1997)Proc. Natl. Acad. Sci.USA 94: pp. 14924-14929.
Labrie et al., Mol. Cell. Endocrinol. 1991, 78: pp. C113-C118.
Langer,Science, 1990, 249, p. 1527.
Levy et al.,Science, 1985, 228, p. 190.
Long, C.D. and Leukins, F.D.W. (1936) J. Exp. Med. 63: pp. 465-549.
Mason, D.,Immunology Today, 1991, 12: 57-60; Rook et al., supra.
Nobel et al., Eur.J. Biochem.2001, 268: pp. 4113-4125.
Peltoketo, et al.,J. Mol. Endocrinol.1999, 23: pp. 1-11.
Penning et al., Biochem. J. 2000, 351: pp. 67-77.
Quattropani, C., et al., “Reduced activity of 11beta-hydroxysteroid dehydrogenase in patients with cholestasis”,J Clin Invest., Nov. 2001: 108 (9), pp. 1299-1305.
Rajan, V.,et al.,Neuroscience, 1996, 16: pp. 65-70.
Raleigh et al.,Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, p. 397.
Langer and Peppas,J Macromol. Sci. Rev. Macromol. Chem., 1983, 23, p. 61.
Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
Rook, G.A.W.,Baillièr's Clin. Endocrinol. Metab., 1999, 13: pp. 576-581.
Sandeep, et al., PNAS, electronically available at www.pnas.org/cgi/doi/10.1073/pnas.0306996101.
Saudek et al.,N. Engl. J Med, 1989, 321, p. 574.
Seckl, J.R., Front. (2000)Neuroendocrinol.18: pp. 49-99.
Seckl, et al.,Endocrinology, 2001, 142: pp. 1371-1376.
Sefton,CRC Crit. Ref Biomed Eng., 1987, 14, 201.
Stokes, J., Noble, et al. “Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues”,Invest Ophthalmol Vis Sci 2000;41(7): pp. 1629-1638.
The Practice of Medicinal Chemistry; Wermuth, C.G., Ed.; Academic Press: New York, 1996; p. 203.
Thompson et al,Tetrahedron lett., 1995, 49, pp. 8937-8940.
Tronche, F. et al.,Nature Genetics, 1999 23: pp. 99-103.
Walker et al.,Hypertension1998, 31: pp. 891-895.
Walker et al., poster P3-698 at the Endocrine society meeting Jun. 12-15, 1999, San Diego.
Woods et al., Science 1998, 280: pp. 1378-1383.
Yau et al., Proc Natl. Acad. Sci. USA 2001, 98: pp. 4716-4721.
Zhuang et al,J. Org. Chem, 2001, 66, pp. 1009-1013.
European Search Report for International Application No. PCT/US2007/012808 mailed on Feb. 15, 2008 (4 pgs.).
Kim et al., “Identification of Substituted 4-Aminopiperidines and 3-Aminopyrrolidines as Potent MCH-R1 Antagonists for the Treatment of Obesity”;Bioorganic&Medicinal Chemistry Letters, 2006, 16( 20), pp. 5445-5450.
Tokita et al., “FK962, a Novel Enhancer of Somatostatin Release, Exerts Cognitive-Enhancing Actions in Rats”,European Journal of Pharmacology, 2005, 527 (1-3), pp. 111-120.
Vasudevan et al., “Identification of Aminopiperidine Benzamides as MCHr1 Antagonists”,Bioorganic&Medicinal Chemistry Letters, 2005, 15(14), pp. 3412-3416.
Powers Jay P.
Rew Yosup
Yan Xuelei
Amgen Inc.
Foley & Lardner LLP
Klinkel Kortney L
Landau Sharmila Gollamudi
LandOfFree
Benzamide derivatives and uses related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamide derivatives and uses related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamide derivatives and uses related thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178917